Abstracts OBJECTIVE: An estimated 1.25 million Americans are chronically infected with hepatitis B virus, many of whom develop severe and potentially fatal liver diseases. Despite the high prevalence and serious health consequences, little is about the impact on quality of life of disease states resulting from chronic HBV infection. The objective was to estimate preferences (ratings and utility weights) for six hepatitis B-related disease states among infected persons. METHODS: Utility weights for six diseaserelated health states were elicited from a sample of 56 patients chronically infected with HBV in San Francisco using a standard gamble. Probability wheels with 2-color pie charts for the relative probabilities of perfect health and death were employed as props. RESULTS: The mean age was 51 y (standard deviation: 12, range: 20 to 77 y) and 77% were men. Mean utilities were: 0.72 (95% confidence interval: 0.68; 0.79) for chronic hepatitis B; 0.70 (0.65; 0.77) for compensated cirrhosis; 0.42 (0.35; 0.47) for decompensated cirrhosis; 0.48 (CI: 0.40; 0.52) for hepatocellular carcinoma; 0.62 (0.56; 0.67) in the first year after liver transplant; and 0.72 (0.65; 0.77) after first year post-transplant. CONCLUSION: These utility values, the first published on patients in the United States, indicate that health states resulting from chronic HBV infection substantially lower patients' qualityof-life. These preferences (utility weights) for health states can be incorporated into many aspects of medical decision making, including summary measures of health related quality of life, monitoring population health, bedside clinical decision making, and in technology assessment. For all health states, the utilities collected here were lower than published estimates that are based on clinicians opinion. 6 Oxford Outcomes, Vancouver, Bristis Columbia, Canada OBJECTIVE: Although the incidence of the hepatitis B virus in the UK is low, persons with chronic infection can develop severe and potentially fatal liver diseases. The objective was to estimate preferences (ratings and utility weights) for six hepatitis B-related disease states among uninfected and infected persons. METHODS: Three hepatologists characterized the typical effects of symptoms on health-related quality of life. Standard gamble (SG) utility weights for six disease-related health states were elicited from a sample of 100 uninfected persons and 87 patients chronically infected with HBV in the UK. Probability wheels with 2-color pie charts for the relative probabilities of perfect health and death were used as props. RESULTS: The mean age of patients was 43 y and 46 y for uninfected persons; and 57% and 47% were men, respectively. For patients and uninfected persons, respectively, mean SG utilities were: 0.77 (95% confi- These utility values, the first published on patients or uninfected persons in the UK, indicate that health states resulting from chronic HBV infection substantially lower patients' quality-of-life. The mean SG utilities were systematically lower for infected than for uninfected persons. These preferences for health states can be incorporated into many aspects of medical decision making, including summary measures of health related quality of life, monitoring population health, bedside clinical decision making, and in technology assessment. To compare the direct health costs of HIVpositive patients reporting sub-optimal intake of antiretroviral therapy (ART) with those of patients reporting full adherence. METHODS: 546 subjects from the Italian multicenter observational study ICoNA (Italian Cohort Naive Antiretrovirals) were followed between 1997 and 2004. Non-adherence to ART was assessed by a self-administered questionnaire. Medical costs incurred by the National Health Service were calculated retrospectively as from first ART and expressed in constant 1997 prices. RESULTS: Mean time on ART was 5.75 years (range 1.04-7.77); mean HIV-RNA and CD4 cells at baseline were 4.75 log 10 copies/ml (range 1.3-6.6) and 307/ml (range 0-1309). Nonadherence was reported by 197 (36%) patients, who showed a higher number of new AIDS-defining events (p = 0.01), of detectable viremia episodes (p < 0.001), and of ART changes (p = 0.01). Overall medical costs and ART costs per year were on average €6392 (range €555-€42,183) and €5373 (range €537-€35,582), respectively, and did not significantly differ between the two groups. Annual inpatient costs were higher in the non-adherent group (€432; 95%CI €256-€608) than in the adherent group (€198; 95%CI €127-€269; p < 0.005). On multivariate linear regression, higher HIV-RNA, lower nadir and baseline CD4, fewer ART changes, and interaction between low adherence and number of therapy switches were independently associated with higher log-transformed ART costs per year. Older age, HCV co-infection, sub-optimal ART adherence, lower CD4 nadir, and higher baseline CD4 were independently associated with higher annual inpatient costs, based on multivariate tobit analysis. CONCLUSIONS: Non-adherence is common among HIV-positive patients and is associated with virological failure, disease progression, more frequent hospitalizations and treatment changes. Total and ART costs do not seem to be significantly affected by non-adherence, probably because of switches to simpler and less expensive treatment options, whereas inpatient costs are significantly increased by sub-optimal drug intake.
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6 Oxford Outcomes, Vancouver, Bristis Columbia, Canada OBJECTIVE: Although the incidence of the hepatitis B virus in the UK is low, persons with chronic infection can develop severe and potentially fatal liver diseases. The objective was to estimate preferences (ratings and utility weights) for six hepatitis B-related disease states among uninfected and infected persons. METHODS: Three hepatologists characterized the typical effects of symptoms on health-related quality of life. Standard gamble (SG) utility weights for six disease-related health states were elicited from a sample of 100 uninfected persons and 87 patients chronically infected with HBV in the UK. Probability wheels with 2-color pie charts for the relative probabilities of perfect health and death were used as props. RESULTS: The mean age of patients was 43 y and 46 y for uninfected persons; and 57% and 47% were men, respectively. For patients and uninfected persons, respectively, mean SG utilities were: 0.77 (95% confi- These utility values, the first published on patients or uninfected persons in the UK, indicate that health states resulting from chronic HBV infection substantially lower patients' quality-of-life. The mean SG utilities were systematically lower for infected than for uninfected persons. These preferences for health states can be incorporated into many aspects of medical decision making, including summary measures of health related quality of life, monitoring population health, bedside clinical decision making, and in technology assessment. To compare the direct health costs of HIVpositive patients reporting sub-optimal intake of antiretroviral therapy (ART) with those of patients reporting full adherence. METHODS: 546 subjects from the Italian multicenter observational study ICoNA (Italian Cohort Naive Antiretrovirals) were followed between 1997 and 2004. Non-adherence to ART was assessed by a self-administered questionnaire. Medical costs incurred by the National Health Service were calculated retrospectively as from first ART and expressed in constant 1997 prices. RESULTS: Mean time on ART was 5.75 years (range 1.04-7.77); mean HIV-RNA and CD4 cells at baseline were 4.75 log 10 copies/ml (range 1.3-6.6) and 307/ml (range 0-1309). Nonadherence was reported by 197 (36%) patients, who showed a higher number of new AIDS-defining events (p = 0.01), of detectable viremia episodes (p < 0.001), and of ART changes (p = 0.01). Overall medical costs and ART costs per year were on average €6392 (range €555-€42,183) and €5373 (range €537-€35,582), respectively, and did not significantly differ between the two groups. Annual inpatient costs were higher in the non-adherent group (€432; 95%CI €256-€608) than in the adherent group (€198; 95%CI €127-€269; p < 0.005). On multivariate linear regression, higher HIV-RNA, lower nadir and baseline CD4, fewer ART changes, and interaction between low adherence and number of therapy switches were independently associated with higher log-transformed ART costs per year. Older age, HCV co-infection, sub-optimal ART adherence, lower CD4 nadir, and higher baseline CD4 were independently associated with higher annual inpatient costs, based on multivariate tobit analysis. CONCLUSIONS: Non-adherence is common among HIV-positive patients and is associated with virological failure, disease progression, more frequent hospitalizations and treatment changes. Total and ART costs do not seem to be significantly affected by non-adherence, probably because of switches to simpler and less expensive treatment options, whereas inpatient costs are significantly increased by sub-optimal drug intake.
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